Veracyte (Decipher)
Veracyte makes the Decipher genomic classifier, the most-used gene-expression test in localised prostate cancer.
Decipher Prostate (22-gene GC) is NCCN level-1 evidence for prognostication in biopsy and post-prostatectomy settings, validated on NRG/RTOG randomised cohorts. Competes conceptually with ArteraAI's digital-pathology test.
Pages like this
not linked directly; found by shared links- TermBethesda category (thyroid cytology)
Shares Thyroid nodule FNA, Bethesda cytology & molecular classifiers, Thyroid cancer.
- IdeaUltrasound restraint and surveillance to reverse thyroid cancer overdiagnosis
Shares Thyroid nodule FNA, Bethesda cytology & molecular classifiers, Thyroid cancer.
- IdeaModern autopsy studies to measure how much silent cancer people carry
Shares Thyroid cancer, Prostate cancer.
- IdeaAn international body to rename indolent lesions so 'cancer' means something
Shares Thyroid cancer, Prostate cancer.
- TermTERT promoter mutation
Shares Thyroid nodule FNA, Bethesda cytology & molecular classifiers, Thyroid cancer.
- ProductArteraAI Prostate
Shares Decipher Prostate, Prostate cancer.
- TermTumour differentiation (well / moderately / poorly differentiated)
Shares Thyroid cancer, Prostate cancer.
- IdeaMolecular indolence classifiers bundled with every screening programme
Shares Thyroid cancer, Prostate cancer.